Guidelines to the treatment of meningioma

FORUM - Trends in Experimental and Clinical Medicine

Volumn 13, Issue 1, 2003, Pages 76-89

  Marosi, Christine ^a   Hassler, Marco ^a   Rössler, Karl ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anti angiogenic therapy; Meningioma; Radiotherapy; Stereotactic radiotherapy; Surgey

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; ANGIOPOIETIN RECEPTOR; COMPLEMENTARY DNA; GESTAGEN; HYDROXYUREA; MIFEPRISTONE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; OCTREOTIDE; PROGESTERONE RECEPTOR; RECOMBINANT PROTEIN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VATALANIB;

AGE DISTRIBUTION; BENIGN TUMOR; BRAIN SURGERY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CELL MEMBRANE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG FEVER; DRUG MECHANISM; FATIGUE; FLU LIKE SYNDROME; GENE DELETION; GENETIC PREDISPOSITION; HUMAN; INTRACRANIAL HYPERTENSION; INTRACRANIAL TUMOR; LEUKOPENIA; LOW ENERGY RADIATION; MENINGIOMA; MENTAL DISEASE; NEUROIMAGING; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOSURGERY; REVIEW; SEX RATIO; SYMPTOMATOLOGY; TOOTH RADIOGRAPHY; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 5344259003     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Rohringer M et al. Incidence and clinicopathological features of meningioma. J. Neurosurg. 1989; 71: 665-672.
2. Lantos PL, van den Berg SR, Kleihues P. Tumours of the nervous system. In: Green-field's Neuropathology, Graham DI, Lantos PL (eds). 6th ed. Arnold: London 1996; 583-879.
3. Rausing A et al. Intracranial meningioma - A population study of ten years. Acta Neurol. Scand. 1970; 46: 102-110.
4. Bondy M and Ligon BL. Epidemiology and etiology of intracranial meningiomas: a review. J. Neurooncol. 1996; 29: 197-205.
5. Longstreth WT et al. Epidemiology of intracranial meningioma. Cancer 1993; 72: 639-648.
6. Louis DN. Meningiomas. In: Kleihues P, Cavenee WK, eds.; Pathology and Genetics of Tumours of the nervous system, WHO Classification of tumours. IARC press, 2000; 176-184.
7. Jääskelainen J et al. The growth rate of intracranial meningiomas and its relation to histology. An analysis of 43 patients. Surg. Neurol. 1985; 24: 165-172.
8. Zankl H and Zang KD. Cytological and cytogenetical studies on brain tumours. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. Humangenetik 1972; 14: 167-169.
9. Sadetzki S et al. Radiation-induced meningioma: a descriptive study of 253 cases. J. Neurosurg. 2002; 97: 1078-1082.
10. Preston-Martin S and White SC. Brain and salivary gland tumours related to prior dental radiography: implications for current practice. J. Am. Dent. Assoc. 1990; 120: 151-158.
11. Annegers J F et al. Head trauma and subsequent brain tumours. Neurosurgery 1979; 4: 203-206.
12. Preston-Martin S et al. An international case-control study of adult glioma and meningioma: the role of head trauma. Int. J. Epidemiol. 1998; 27: 579-586.
13. Phillips LE et al. History of head trauma and risk of intracranial meningioma: population-based case-control study. Neurology 2002; 58: 1849-1852.
14. Inoue T et al. Progesterone, production and actions in the human central nervous system and neurogenic tumours. J. Clin. Endocrinol. Metab. 87: 5325-5331.
15. Carroll RS et al. Progesterone receptor expression in meningiomas. Cancer Res. 1993; 53: 1312-1316.
16. Helseth A, Mork S, J Glattre E. Neoplasms of the central nervous system in Norway. V. Meningioma and cancer of other sites. An analysis of the occurrence of multiple primary neoplasms in meningioma patients in Norway from 1955 through 1986. Apmis 1989; 97: 738-744.
17. Schoenberg BS and Christine BW. Neoplasms of the brain and cranial meninges: a study of incidence, epidemiological trends, and survival. Neurology 1970; 20: 399.
18. Probst-Cousin S et al. Secretory meningioma: clinical, histologic, and immunohistochemical findings in 31 cases. Cancer 1997; 79: 2003-2015.
19. Kleihues P. Histological typing of tumours of the central nervous system. Springer-Verlag, Berlin, 1993.
20. Weber RG et al. Analysis of genomic alterations in benign, atypical, and anaptastic meningiomas: toward a genetic model of meningioma progression. Proc. Natl. Acad. Sci. USA 1997; 94: 14719-14724.
21. Bindal R et al. The natural history of untreated skull base meningiomas. Surg. Neurol. 2003; 59: 87-92; discussion 92.
22. Hodges F. Meningiomas. In: Ferucci JT, ed.; Radiology: diagnosis-imaging-intervention, vol. 3: Neuroradiology and radiology of the head and neck. Philadelphia: JB Lippinkott, 1989.
23. Russell EJ et al. Atypical computed tomography features of intracranial meningioma: radiological-pathological correlation in a series of 131 consecutive cases. Radiology 1980; 135: 673-682.
24. Elster AD et al. Meningiomas: MR and histopathologic features. Radiology 1989; 170: 857-862.
25. Yoshikawa T et al. Time-resolved two-dimensional thick-slice magnetic resonance digital subtraction angiography in assessing brain tumours. Eur. Radiol. 2000; 10: 736-744.
26. Galanaud D et al. Contribution of magnetic resonance spectrometry to the diagnosis of intracranial tumours. Ann. Med. Interne (Paris) 2002; 153: 491-498.
27. Majos C et al. Utility of proton MR spectroscopy in the diagnosis of radiologically atypical intracranial meningiomas. Neuroradiology 2003; 45: 129-136.
28. McCutcheon IE. The biology of meningiomas. J. Neurooncol. 1996; 29: 207-216.
29. Adegbite AB et al. The recurrence of intracranial meningiomas after surgical treatment. J. Neurosurg. 1983; 58: 51-56.
30. Mirimanoff RO et al. Meningioma: analysis of recurrence and progression following neurosurgical resection. J. Neurosurg. 1985, 62: 18-24.
31. Taylor BW, Jr et al.The meningioma controversy: postoperative radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1988; 15: 299-304.
32. Glaholm J, Bloom HJ, Crow JH. The role of radiotherapy in the management of intracranial meningiomas: the Royal Marsden Hospital experience with 186 patients. Int. J. Radiat. Oncol. Biol. Phys. 1990; 18: 755-761.
33. Goldsmith BJ et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J. Neurosurg. 1994, 80: 195-201.
34. Mahmood A, Qureshi NH, Malik GM. Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir. 1994; 126:53-58,
35. Condra KS et al. Benign meningiomas: primary treatment selection affects survival. Int. J. Radiat. Oncol. Biol. Phys. 1997; 39: 427-436.
36. Stafford SL et al. Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin. Proc. 1998; 73: 936-42.
37. Nutting C et al. Radiotherapy in the treatment of benign meningioma of the skull base. J. Neurosurg. 1999; 90: 823-827,
38. Ayerbe J et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma. A multivariate analysis. Acta Neurochir. 1999; 141: 921-932.
39. Debus J et al. High efficacy of fractionated stereotactic radiotherapy of large base- of-skull meningiomas: long-term results. J. Clin. Oncol. 2001; 19: 3547-3553.
40. Flickinger J and Kondziolka D. Gamma knife radiosurgery of imaging-diagnosed intracranial meningioma. Int. J. Radiat. Oncol. Biol. Phys. 2003; 56: 801-806.
41. Wolbers JG et al. Benign' meningioma. Ned. Tijdschr. Geneeskd. 2001; 145: 2153-2157.
42. Braunstein JB and Vick NA. Meningiomas: the decision not to operate. Neurology 1997; 48: 1459-1462.
43. Al-Mefty O. Meningiomas, New York: Raven Press, 1991.
44. Ausman JI. Meningiomas-the future: is 2020 here? Surg. Neurol. 2003; 59: 140-141.
45. Miralbell R et al. The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J. Neurooncol. 1992; 13: 157-164.
46. Bloom HJ. Intracranial tumours: response and resistance to therapeutic endeavors, 1970-1980. Int. J. Radiat. Oncol. Biol. Phys. 1982; 8: 1083-1113.
47. Carella R and Ransohoff J. Role of radiation therapy in the management of meningioma. Neurosurgery 1982; 10: 332-329.
48. Simpson WJ. The recurrence of intracranial meningiomas after surgical treatment. J. Neurol. Neurosurg. Psychiatry 1957; 20: 2208-2213.
49. Borovich B et al. Recurrence of intracranial meningiomas: the role played by regional multicentricity. Part 2: Clinical and radiological aspects. J. Neurosurg. 1986; 65: 168-171.
50. Kondziolka D et al. Long-term outcomes after meningioma radiosurgery: physician and patient perspectives, J. Neurosurg. 1999; 91: 44-50.
51. Maire JP et al. Fractionated radiation therapy in the treatment of intracranial meningiomas: local control, functional efficacy, and tolerance in 91 patients. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 315-321.
52. Wellis G et al. Direct costs of microsurgical management of radiosurgically amenable intracranial pathology in Germany: an analysis of meningiomas, acoustic nEuromas, metastases and arteriovenous malformations of less than 3 cm in diameter. Acta Neurochir. (Wien) 2003; 145: 249-255.
53. Jaffrain-Rea ML et al. Visual improvement during octreotide therapy in a case of episellar meningioma. Clin. Neurol. Neurosurg. 1998; 100: 40-43.
54. Prat R, Banzo J, Diaz FJ. Somatostatin receptors in meningioma: diagnostic and therapeutic value. Rev. Neurol. 1997; 25: 2002-2005.
55. Edwards DP et al. Progesterone receptor and the mechanism of action of progesterone antagonists. J. Steroid Biochem. Mol. Biol. 1995; 53: 449-458.
56. Stewart DJ et al. Intraarterial cisplatin plus intravenous doxorubicin for inoperable recurrent meningiomas. J. Neurooncol. 1995; 24: 189-194.
57. Cusimano MD. Hydroxyurea for treatment of meningioma. J. Neurosurg. 1998; 88: 938-939.
58. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy for unresectable or residual meningioma. J. Neurooncol. 2000; 49: 165-170.
59. Mason WP et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J. Neurosurg. 2002; 97: 341-346.
60. Schrell UM et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J. Neurosurg. 1997; 86: 840-844.
61. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J. Clin. Neurosci. 2002; 9: 156-158.
62. Muhr C et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin. Cancer Res. 2001; 7: 2269-2276.
63. Koper JW et al. Inhibition of the growth of cultured human meningioma cells by recombinant interferon-alpha. Eur. J. Cancer 1991; 27: 416-419.
64. Kaba SE et al. The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997; 40: 271-275.
65. Chaubal A et al. CD34 immunoreactivity in nervous system tumours. Acta Neuropathol. 1994; 88: 454-458.
66. Reinmuth N et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab. Invest. 2002; 82: 1377-1389.
67. Reinmuth N et al. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J. 2001; 15: 1239-1241.
68. Reinmuth N et al. Biology of angiogenesis in tumours of the gastrointestinal tract. Microsc. Res. Tech. 2003; 60: 199-207.
69. Reinmuth N et al. Endothelial survival factors as targets for antineoplastic therapy. Cancer J. 2001; 7 (Suppl 3): S109-119.
70. Paek S H et al. Correlation of clinical and biological parameters with peritumoural edema in meningioma. J. Neurooncol. 2002; 60: 235-245.
71. Johnson MD et al. Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J. Neurooncol. 2002; 56: 133-142.
72. Kirsch M et al. Therapeutic anti-angiogenesis for malignant brain tumours. Onkologie 2001; 24: 423-430.
73. Cummings TJ, Burchette JL, McLendon RE. CD34 and dural fibroblasts: the relationship to solitary fibrous tumour and meningioma. Acta Neuropathol. (Berl) 2001; 102: 349-354.
74. Puduvalli VK and Sawaya R. Antiangiogenesis - therapeutic strategies and clinical implications for brain tumours. J. Neurooncol. 2000; 50: 189-200.
75. McMahon G. VEGF receptor signaling in tumour angiogenesis. Oncologist 2000; 5: 3-10.
76. Machein MR and Plate KH. VEGF in brain tumours. J. Neurooncol. 2000; 50: 109-120.
77. Lutchman M and Rouleau GA. The neurofibromatosis type 2 gene product, schwannomin, suppresses growth of NIH 3T3 cells. Cancer Res. 1995; 55: 2270-2274.
78. Sherman L et al. Interdomain binding mediates tumour growth suppression by the NF2 gene product. Oncogene 1997; 15: 2505-2509.
79. Cerda-Nicolas M et al. Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumours. Clin. Neuropathol. 2000, 19: 259-267.
80. Roessler K, Gatterbauer B, Kitz K. Topoisomerase II alpha as a reliable proliferation marker in meningiomas. Neurol. Res. 2002; 24: 241-243.
81. Yoshioka H et al. Peritumoural brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer 1999; 85: 936-944.
82. Harland SP et al. Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery 1998; 43: 890-898; discussion 898-899.
83. Johnson MD et al. Transforming growth factor-beta and transforming growth factor beta-receptor expression in human meningioma cells. Am. J. Pathol. 1992; 141: 633-642.